Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Alex admits some patients preemptively even when outpatient dosing is possible: those living alone with limited support, patients with heart failure or chronic kidney disease, and those with high tumor burden, LDH above 1,000, or malignant effusions. The aim is faster recognition and treatment of CRS.

Related Insights

A critical logistical challenge for administering Tarlatumab is ensuring patients with fever (a potential sign of CRS) are not left waiting in a standard emergency room. An effective strategy involves creating a dedicated protocol so these patients are seen immediately by staff familiar with the drug's toxicities, preventing dangerous delays.

Advanced SCLC therapies like the bispecific antibody tarlatumab require inpatient administration for the first two doses to manage severe side effects like Cytokine Release Syndrome (CRS). Many community centers lack the specialized cellular therapeutics or transplant teams necessary for this complex monitoring, creating an implementation gap.

For frail elderly patients, it's crucial to discern if poor performance status stems from disease or comorbidities. A practical approach is to initiate treatment with biologic agents alone. If the patient's status improves, it confirms the cancer is the cause, justifying the subsequent, careful addition of cytotoxic chemotherapy.

For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.

Alex and Jennifer describe a 'pill in pocket' approach: patients keep dexamethasone at home. If they call with fever but stable vital signs, they take one dose, monitor temperature every one to two hours, and call back for recurrent fever. Many avoid admission, though repeat fever triggers evaluation.

For acutely ill patients with strong clinical suspicion of SCLC, delaying treatment for biopsy confirmation can mean losing the window for effective intervention. Initiating chemotherapy in the hospital based on clinical presentation is a critical, potentially life-saving measure.

In complex, real-world CLL cases with elderly patients and comorbidities, the 'art of medicine' prevails. Opting for a less intensive, guideline-deviant therapy like single-agent obinutuzumab can be a reasonable choice to control symptoms and improve quality of life, prioritizing safety over maximal PFS.

A quarter of patients with metastatic prostate cancer die from cardiovascular disease, not their cancer. This statistic mandates that oncologists actively manage patient comorbidities by assembling a specialist team, engaging primary care, and emphasizing lifestyle interventions alongside cancer treatment to improve overall survival.

Clinicians can avoid treatment delays and unnecessary fluid administration by having patients start sodium bicarbonate before hospital admission. This proactive strategy ensures the patient's urine is appropriately alkalized, allowing high-dose methotrexate to be administered safely and on schedule.

While initial doses of the BiTE therapy tarlatumab require inpatient monitoring for CRS and ICANS, experienced centers are shifting to outpatient administration for subsequent cycles. This is typically for low-risk patients with good support who live nearby, signaling a move towards more manageable community use.